Characteristics of patients initiating treatment with baricitinib and outcomes at follow-up: analysis of BSRBR-RA Registry data.

"Disclosure statement : C.J.E. has received fees from Abbvie, Astra Zeneca, Fresenius Kabi, Gilead, Galapagos, GSK, Janssen, Eli Lilly and Company, Pfizer, Roche, Sanofi for advisory boards, speakers bureau and research support. J.M., M.S., T.G., A.M. and E.L. are employees of Eli Lilly and Company. J.M., M.S., T.G. and E.L. are shareholders of Eli Lilly and Company. L.Z.-P. is a consultant from HaaPACS. E.D. has received honoraria and speaker fees from UCB, Pfizer, Viatris and Eli Lilly and Company."

"Funding This work was supported by Eli Lilly and Company. Medical writing services were provided by Caroline Spencer and Dr Sue Chambers (Rx Communications, Mold, UK), funded by Eli Lilly and Company. Disclosure statement: C.J.E. has received fees from Abbvie, Astra Zeneca, Fresenius Kabi, Gilead, Galapagos, GSK, Janssen, Eli Lilly and Company, Pfizer, Roche, Sanofi for advisory boards, speakers bureau and research support. J.M., M.S., T.G., A.M. and E.L. are employees of Eli Lilly and Company. J.M., M.S., T.G. and E.L. are shareholders of Eli Lilly and Company. L.Z.-P. is a consultant from HaaPACS. E.D. has received honoraria and speaker fees from UCB, Pfizer, Viatris and Eli Lilly and Company."